Akoya BioSciences Inc. (AKYA) Financial Statements (2025 and earlier)

Company Profile

Business Address 100 CAMPUS DRIVE
MARLBOROUGH, MA 01762
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 3826 - Laboratory Analytical Instruments (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments83,12581,218113,079
Cash and cash equivalents83,12574,229113,079
Short-term investments 6,989 
Other undisclosed cash, cash equivalents, and short-term investments   
Receivables16,9949,7299,444
Inventory, net of allowances, customer advances and progress billings17,87714,4869,014
Inventory17,87714,4869,014
Other current assets3,7946,7649,277
Other undisclosed current assets   
Total current assets:121,790112,197140,814
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization1,5621,490 
Operating lease, right-of-use asset8,36510,785 
Property, plant and equipment10,72910,1747,487
Long-term investments and receivables   
Long-term investments   
Intangible assets, net (including goodwill)35,67438,31039,412
Goodwill18,26218,26218,262
Intangible assets, net (excluding goodwill)17,41220,04821,150
Restricted cash and investments699303302
Deferred costs 7461,372600
Other noncurrent assets657688344
Other undisclosed noncurrent assets1477121,948
Total noncurrent assets:58,57963,83450,093
TOTAL ASSETS:180,369176,031190,907
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities25,20927,14722,926
Accounts payable11,77610,6289,435
Accrued liabilities13,43316,51913,491
Deferred revenue6,6886,2794,484
Debt767620272
Other undisclosed current liabilities2,6813,009 
Total current liabilities:35,34537,05527,682
Noncurrent Liabilities
Long-term debt and lease obligation76,02063,95232,668
Long-term debt, excluding current maturities75,25463,27732,471
Finance lease, liability766675197
Liabilities, other than long-term debt15,23416,4439,206
Deferred revenue3,1932,1141,330
Deferred income tax liabilities388726
Other liabilities   
Operating lease, liability6,2388,203 
Business combination, contingent consideration, liability5,7656,0397,850
Total noncurrent liabilities:91,25480,39541,874
Total liabilities:126,599117,45069,556
Equity
Equity, attributable to parent, including:53,77058,581121,351
Common stock22 
Additional paid in capital283,839225,333217,456
Accumulated other comprehensive income (loss) (6) 
Accumulated deficit(230,071)(166,748)(96,107)
Other undisclosed equity, attributable to parent   2
Total equity:53,77058,581121,351
TOTAL LIABILITIES AND EQUITY:180,369176,031190,907

Income Statement (P&L) ($ in thousands)

9/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
Revenues96,63374,85954,917
Cost of revenue(40,328)(31,469)(20,699)
Gross profit:56,30543,39034,218
Operating expenses(113,973)(109,496)(73,516)
Operating loss:(57,668)(66,106)(39,298)
Nonoperating expense
(Other Nonoperating expense)
(343)(635)(410)
Interest and debt expense(142)(60)2,476
Loss from continuing operations before equity method investments, income taxes:(58,153)(66,801)(37,232)
Other undisclosed loss from continuing operations before income taxes(5,130)(3,717)(5,843)
Loss from continuing operations before income taxes:(63,283)(70,518)(43,075)
Income tax expense (benefit)(40)(123)140
Loss from continuing operations:(63,323)(70,641)(42,935)
Loss before gain (loss) on sale of properties:(42,935)
Net loss attributable to parent:(63,323)(70,641)(42,935)
Preferred stock dividends and other adjustments   (1,435)
Net loss available to common stockholders, diluted:(63,323)(70,641)(44,370)

Comprehensive Income ($ in thousands)

9/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
Net loss:(63,323)(70,641)(42,935)
Comprehensive loss:(63,323)(70,641)(42,935)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent6(6) 
Comprehensive loss, net of tax, attributable to parent:(63,317)(70,647)(42,935)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: